查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2016949

血管移植物市場：2026-2032年全球市場預測（依產品類型、血管直徑、適應症、最終用戶及通路分類）

Vascular Graft Market by Product Type, Blood Vessel Diameter, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，血管移植市場價值將達到 18 億美元，到 2026 年將成長到 19 億美元，到 2032 年將達到 27.8 億美元，複合年成長率為 6.44%。

主要市場統計數據
基準年 2025 18億美元
預計年份：2026年 19億美元
預測年份 2032 27.8億美元
複合年成長率 (%) 6.44%

本文對塑造血管移植應用和策略下一時代的關鍵臨床、技術和商業性挑戰進行了簡潔且專業的概述。

血管移植領域正處於關鍵的轉折點，其驅動力來自臨床需求、材料創新和不斷發展的醫療服務模式的整合。血管移植用於修復或取代受損血管，其應用範圍涵蓋心血管外科到周邊血管介入等許多領域，隨著人口結構變化導致血管疾病盛行率上升，血管移植的重要性也日益凸顯。生物材料和製造技術的進步拓展了臨床醫生的選擇範圍，術前術後護理和影像技術的改進也正在改變治療決策的方式。因此，醫療服務提供者和採購團隊必須在臨床療效需求、營運限制和報銷趨勢之間取得平衡。

臨床實務的進步、材料的創新以及通路的現代化，是如何重塑整個血管移植生態系統的競爭格局的？

由於材料科學的突破、臨床方案的轉變以及從集中式醫院治療向門診治療的轉變，血管移植生態系統正在經歷一場變革。生物材料和合成聚合物的創新使得移植血管能夠更精確地模擬體內血液動力學並降低血栓形成風險，而混合結構和表面改質技術則拓展了其適用範圍。同時，手術流程也在不斷發展。微創手術和混合手術室的應用日益普及，改變了手術全期工作流程和醫療設備的兼容性要求。

我們評估不斷變化的貿易措施和關稅趨勢如何重塑血管移植相關人員的採購決策、供應鏈韌性和籌資策略。

由於關稅及相關貿易措施會影響籌資策略和成本結構，政策和貿易工具正在為供應鏈計算和採購計劃引入新的變數。關稅帶來的成本壓力促使製造商和醫療系統重新評估其供應商中心，探索近岸外包和回流方案，並修訂長期合約以降低風險。這些應對措施不僅限於商業性；它們還會影響臨床運營，因為採購計劃和庫存政策需要進行調整，以確保醫療服務的連續性並維持所需移植材料的供應。

一個複雜的細分框架，將產品材料、尺寸、適應症、最終用戶環境和分銷管道與臨床應用和商業策略聯繫起來。

市場區隔提供了一個分析框架，用於理解不同產品類型導入模式和臨床適用性方面的差異。從產品類型角度來看，生物基血管移植物和合成血管移植物之間的差異十分顯著：生物基移植物，包括同種異體移植、自體移植和異質骨移植，具有固有的生物相容性優勢，但通常需要特殊的處理和供體獲取方面的考慮。合成材料，例如聚酯、聚四氟乙烯和聚氨酯，具有生產一致性和可擴展的供應鏈，但需要解決血栓形成和長期通暢性方面的問題。這些材料和處理方面的差異直接影響臨床醫生的選擇和庫存管理。

決定全球主要市場採購偏好、臨床引進管道和分銷策略的區域趨勢和醫療保健系統特徵。

區域趨勢對整個血管移植物市場的臨床實踐模式、監管預期和供應鏈結構產生顯著影響。在美洲，完善的臨床基礎設施和複雜的醫保體係要求提供強力的長期證據和高性能的醫療器材。同時，大規模獨立經銷商的存在也影響著分銷策略和庫存管理實踐。在歐洲、中東和非洲，各國醫療保健體系的多樣性要求制定適應性強的監管策略和彈性價格設定方法；有些市場優先考慮便攜性和成本效益，而有些市場則優先考慮創新和高性能解決方案。亞太地區呈現出都市區臨床容量快速擴張和發展中市場成本意識強的雙重特徵，這為高級產品和具成本效益產品都創造了機會。

影響血管移植領域領導地位的關鍵競爭定位因素，重點在於臨床證據、製造能力、策略夥伴關係關係和商業化模式。

血管移植物領域的競爭優勢取決於臨床證據、材料創新、生產可靠性、法規遵循和強大的銷售管道的綜合運用。成熟的製造商憑藉其一體化的生產和上市後監測能力，利用自身良好的業績記錄與大規模醫院系統和學術機構合作。他們通常會將產品系列與培訓和臨床支援項目結合，從而提升產品的市場偏好。新興企業和Start-Ups則透過新型生物材料、表面工程技術和針對特定適應症脫穎而出，力求在特定臨床場景中展現其臨床優勢或獨特的易用性。

為製造商和醫療保健領導者提供可操作的策略重點，以增強血管移植物的臨床證據、供應彈性和個人化商業化。

產業領導者必須推動一系列協調一致的舉措，從臨床、營運和商業等各個方面著手，以實現長期價值。優先進行針對特定適應症的嚴格臨床檢驗，特別是將真實世界性能註冊研究和上市後監測與證據生成相結合，有助於加強醫保報銷談判，並提升臨床醫生的信心。同時，投資於材料科學領域的創新，例如生物基支架、混合結構或表面改質技術，可以透過提高血管通暢率和降低併發症率，實現顯著的差異化優勢。

簡要介紹用於整合臨床、商業和供應鏈見解的證據來源、相關人員諮詢和分析方法。

本研究的綜合分析是基於對同行評審的臨床文獻、監管文件、專利趨勢、公開的臨床註冊數據以及與臨床醫生、供應鏈負責人和商業專業人士的訪談的系統性回顧。關鍵的定性資料透過結構化諮詢取得，以檢驗臨床偏好、器械操作注意事項和採購趨勢。二級資訊來源提供了材料科學趨勢、器械核准情況和操作指南方面的背景信息，從而能夠對來自不同證據來源的見解進行三角驗證。

策略整合強調臨床檢驗、材料創新和供應韌性的整合，以此作為血管移植技術持續應用的基礎。

總而言之，血管移植領域正以多種方式成熟。人們對臨床證據的期望日益提高，材料和製造技術的創新不斷拓展治療的可能性，供應鏈和分銷策略也因政策和物流因素而重新評估。這些並行發展形成了一個複雜的環境，其中臨床表現、營運韌性和監管合規性都發揮著至關重要的作用。對於相關人員，成功需要一項整合策略，該策略需結合嚴謹的證據產生、靈活的生產製造和客製化的商業性執行。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：血管移植市場：依產品類型分類

  • 生物血管移植物
    • 同種異體移植
    • 自體移植
    • 異質骨移植
  • 人工血管移植
    • 聚酯纖維
    • 聚四氟乙烯
    • 聚氨酯

第9章：以血管直徑分類的血管移植市場

  • 大的
  • 小的

第10章：血管移植市場：依適應症分類

  • 主動脈和髂動脈旁路手術
  • 腦動脈繞道手術
  • 冠狀動脈繞道術
  • 下肢搭橋手術
  • 周邊動脈旁路手術
  • 腎動脈繞道手術

第11章：血管移植市場：依最終用戶分類

  • 門診手術中心
  • 醫院和診所

第12章：血管移植市場：依通路分類

  • 離線
  • 線上

第13章：血管移植市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：血管移植市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 血管移植市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國血管移植市場

第17章：中國血管移植市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Affluent Medical
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • BIOVIC Sdn. Bhd.
  • Boston Scientific Corporation
  • Cardinal Health Inc.
  • Cook Medical, Inc.
  • Corcym Srl
  • CryoLife, Inc.
  • Endologix Inc.
  • Getinge AB
  • Heart Medical Europe BV
  • Japan Lifeline Co., Ltd.
  • Lemaitre Vascular, Inc.
  • Medtronic PLC
  • Merit Medical Systems, Inc.
  • Perouse Medical SAS by Vygon SAS
  • Rua Life Sciences PLC
  • Shanghai Suokang Medical Implants Co. Ltd.
  • Terumo Corporation
  • Vascular Graft Solutions Ltd.
  • VUP Medical
  • WL Gore & Associates, Inc.
  • Xeltis BV
Product Code: MRR-034B50030374

The Vascular Graft Market was valued at USD 1.80 billion in 2025 and is projected to grow to USD 1.90 billion in 2026, with a CAGR of 6.44%, reaching USD 2.78 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.80 billion
Estimated Year [2026] USD 1.90 billion
Forecast Year [2032] USD 2.78 billion
CAGR (%) 6.44%

A concise professional framing of the clinical, technological, and commercial imperatives shaping the next era of vascular graft utilization and strategy

The vascular graft landscape is at a pivotal inflection point driven by converging clinical demand, material innovations, and evolving care delivery models. Vascular grafts, which restore or replace compromised blood vessels, intersect disciplines ranging from cardiovascular surgery to peripheral vascular interventions, and their relevance continues to expand as demographic shifts increase the prevalence of vascular disease. Advances in biomaterials and manufacturing have broadened options for clinicians, while improvements in perioperative care and imaging are reshaping procedural decision-making. Consequently, healthcare providers and procurement teams must reconcile clinical performance needs with operational constraints and reimbursement dynamics.

Against this backdrop, stakeholders require a clear, clinically grounded synthesis of product attributes, use-case differentiation, regulatory pathways, and distribution considerations. This introduction frames the subsequent analysis by establishing the clinical imperatives that drive graft selection, the technological levers that create differentiation, and the commercial mechanisms that influence adoption. By linking clinical utility to strategic choices, the section sets the stage for pragmatic decision-making across product development, supply chain optimization, and clinical adoption pathways. Transitioning from foundational understanding to strategic insight, the remainder of the executive summary examines structural changes, tariff implications, segmentation idiosyncrasies, regional dynamics, competitive positioning, recommended actions, research approach, and concluding imperatives.

How clinical practice evolution, materials innovation, and distribution modernization are restructuring competitive dynamics across the vascular graft ecosystem

The vascular graft ecosystem is experiencing transformative shifts driven by material science breakthroughs, shifting clinical protocols, and a reorientation of care delivery away from centralized hospital settings toward outpatient and ambulatory modalities. Innovations in biologics and synthetic polymers are enabling grafts that better mimic native hemodynamics and reduce thrombogenicity, while hybrid constructs and surface modifications are expanding the range of viable indications. At the same time, procedural pathways are evolving: minimally invasive approaches and hybrid operating suites are becoming more prevalent, altering the perioperative workflow and device compatibility requirements.

Concurrently, regulatory scrutiny and quality standards have intensified, prompting manufacturers to invest in robust evidence generation and post-market surveillance. Supply chain resilience and distribution agility have come into sharper focus, with stakeholders prioritizing multiple sourcing strategies and deeper distributor partnerships. These shifts are compounded by an accelerated digital adoption in procurement and clinician education, which supports faster dissemination of clinical data and device use protocols. Taken together, these dynamics create both disruption and opportunity; companies that align R&D priorities with changing clinician workflows and invest in rigorous clinical validation will be positioned to capture expanding clinical use cases and sustain longer-term adoption.

Assessing how evolving trade measures and tariff dynamics are reshaping sourcing decisions, supply chain resiliency, and procurement strategies for vascular graft stakeholders

Policy and trade instruments have introduced a new variable into supply chain calculus and procurement planning, as tariffs and related trade measures influence sourcing strategies and cost structures. Tariff-driven cost pressures have prompted manufacturers and health systems to reassess supplier footprints, consider nearshoring or reshoring options, and revisit long-term contracts to mitigate exposure. These responses are not solely commercial; they also affect clinical operations, as procurement timelines and inventory policies are adjusted to ensure continuity of care and to preserve access to preferred graft types.

Healthcare organizations are increasingly conducting total-cost-of-ownership analyses that incorporate tariff impacts, logistics volatility, and potential delays. In parallel, manufacturers are evaluating tariff mitigation approaches such as tariff engineering, alternative routing, localization of key components, and strategic partnerships with regional contract manufacturers. The net effect is a realignment of distribution networks and a heightened emphasis on multi-tiered contingency planning. As stakeholders adapt, collaboration between clinical leaders, procurement teams, and supply chain experts becomes essential to balance cost containment with clinical performance imperatives and to ensure that patient care pathways remain uninterrupted despite geopolitical and policy fluctuations.

A nuanced segmentation framework linking product materials, sizing, indications, end-user environments, and distribution channels to clinical adoption and commercial strategy

Segmentation provides the analytical scaffolding to understand differential adoption patterns and clinical fit across product categories, sizes, indications, end users, and distribution channels. When viewed through the lens of product type, distinctions between Biological Vascular Grafts and Synthetic Vascular Grafts become salient: biological options encompassing allografts, autografts, and xenografts bring inherent biocompatibility advantages but often require specialized handling and donor-sourcing considerations, whereas synthetic offerings such as polyester, polytetrafluoroethylene, and polyurethane deliver manufacturing consistency and scalable supply chains but must address thrombogenicity and long-term patency concerns. These material and handling differences directly influence clinician preference and inventory management.

Blood vessel diameter segmentation into large and small categories further refines clinical decision-making because sizing constraints and flow dynamics alter graft selection criteria and surgical technique. Indication-focused segmentation underscores that procedural contexts-ranging from aortoiliac bypass surgery and cerebral artery bypass surgery to coronary artery bypass surgery, lower extremity bypass, peripheral artery bypass, and renal artery bypass-impose unique hemodynamic and anatomic demands that affect device design and evidence requirements. End-user distinctions between ambulatory surgical centers and hospitals and clinics highlight divergent procedural volumes, staffing models, and procurement capabilities, which in turn influence preferred product portfolios. Finally, distribution channel segmentation across offline and online pathways shapes how products reach clinicians and purchasers; offline channels continue to support hands-on training and logistics for complex devices, while online channels accelerate information access and volume-based procurement. By integrating these segmentation dimensions, stakeholders can more precisely target development, clinical evidence generation, and commercial strategies to meet differentiated clinical and operational needs.

Regional dynamics and health system nuances that determine procurement preferences, clinical adoption pathways, and distribution strategies across major global markets

Regional dynamics exert a profound influence on clinical practice patterns, regulatory expectations, and supply chain architectures across the vascular graft landscape. In the Americas, health systems exhibit a mix of advanced clinical infrastructure and complex reimbursement ecosystems that drive demands for robust long-term evidence and high-performance devices, while the presence of large independent distributors affects channel strategies and inventory practices. In Europe, Middle East & Africa, heterogeneity across national healthcare systems requires adaptable regulatory strategies and flexible pricing approaches, with some markets emphasizing portability and cost-effectiveness and others prioritizing innovation and premium-performance solutions. The Asia-Pacific region presents a dual dynamic of rapidly expanding clinical capacity in urban centers alongside cost-sensitive procurement in developing markets, creating opportunities for both premium and value-focused product offerings.

Across these regions, differences in physician training pathways, procedural volumes, and hospital versus ambulatory care balance shape adoption curves for specific graft types and technologies. Supply chain implications also vary: proximity to manufacturing hubs, regional trade agreements, and logistics infrastructure affect lead times and inventory management. Consequently, companies pursuing geographic expansion must tailor their clinical engagement, regulatory submissions, and distribution partnerships to regional idiosyncrasies while maintaining consistent quality and evidence standards. Strategic regional alignment, informed by local clinical champions and operational partners, will be critical to unlocking sustained adoption across disparate healthcare systems.

Competitive positioning essentials emphasizing clinical evidence, manufacturing strength, strategic partnerships, and commercialization models that influence leadership in the vascular graft sector

Competitive positioning in the vascular graft domain rests on a combination of clinical evidence, material innovation, manufacturing reliability, regulatory compliance, and channel strength. Established manufacturers with integrated manufacturing and post-market surveillance capabilities leverage their track record to engage large hospital systems and academic centers, often coupling product portfolios with training and clinical support programs to drive preference. Emerging players and startups are differentiating through novel biomaterials, surface-engineering approaches, and targeted indications, seeking to demonstrate clinical superiority or differentiated ease of use in focused clinical scenarios.

Partnerships between device developers and contract manufacturers or specialty coating suppliers are increasingly common as companies accelerate time-to-clinic while controlling capital intensity. Distribution strategies range from deep direct-sales relationships in high-touch hospital environments to hybrid models that employ third-party distributors and e-commerce platforms for routine replenishment. In addition, strategic alliances with clinical research networks and registry platforms enable firms to generate high-quality real-world evidence that supports formulary inclusion and clinician adoption. Ultimately, companies that effectively align R&D priorities with scalable manufacturing and a differentiated commercial approach will be better positioned to navigate reimbursement pressures and clinician expectations while protecting long-term revenue streams.

Actionable strategic priorities for manufacturers and healthcare leaders to strengthen clinical evidence, supply resilience, and tailored commercialization for vascular grafts

Industry leaders must pursue a coordinated set of actions that address clinical, operational, and commercial dimensions to capture long-term value. Prioritizing rigorous clinical validation for targeted indications will strengthen reimbursement discussions and clinician confidence, especially when evidence generation is coupled with registries and post-market surveillance that demonstrate real-world performance. Simultaneously, investing in material science initiatives-whether in biologic scaffolds, hybrid constructs, or surface-modification technologies-can create meaningful differentiation by improving patency and reducing complication rates.

Operationally, diversifying manufacturing footprints and developing contingency sourcing plans will mitigate tariff and logistics risks, while partnerships with regional manufacturers can accelerate market entry and lower lead times. Commercially, tailored go-to-market strategies that recognize differences between ambulatory surgical centers and hospitals and clinics will improve uptake; high-touch education and hands-on training are critical in complex procedures, whereas streamlined procurement and repeatable logistics support scale in high-volume contexts. Finally, embracing digital channels for clinician engagement and leveraging online distribution for routine replenishment can complement traditional sales models. By implementing these integrated recommendations, organizations can enhance resilience, foster clinician trust, and align product offerings with evolving care delivery norms.

A concise description of the evidence sources, stakeholder consultations, and analytical approaches used to synthesize clinical, commercial, and supply chain insights

This research synthesis is grounded in a systematic review of peer-reviewed clinical literature, regulatory documentation, patent landscapes, publicly available clinical registries, and stakeholder interviews with clinicians, supply chain leaders, and commercial experts. Primary qualitative inputs were obtained through structured consultations to validate clinical preferences, device handling considerations, and procurement dynamics. Secondary sources provided context on material science trends, device approvals, and procedural guidelines, enabling triangulation of insights across evidence streams.

Analytical approaches included comparative evaluation of device attributes against clinical requirements for different indications and diameters, assessment of distribution channel efficacy, and scenario analysis to examine the implications of tariff-induced supply chain adjustments. Care was taken to corroborate assertions with multiple independent sources and to distinguish established clinical consensus from emerging hypotheses. Throughout, emphasis was placed on actionable insight rather than raw enumeration of datasets, ensuring that findings are directly relevant to product strategy, clinical engagement, and procurement planning. Where appropriate, limitations and areas requiring further primary data collection are noted to guide follow-up research and evidence generation efforts.

A strategic synthesis highlighting the convergence of clinical validation, material innovation, and supply resilience as the foundation for sustained adoption of vascular graft technologies

In sum, the vascular graft landscape is maturing along multiple dimensions: clinical evidence expectations are rising, material and manufacturing innovations are expanding therapeutic possibilities, and supply chain and distribution strategies are being recalibrated in response to policy and logistical factors. These concurrent developments create a complex environment in which clinical performance, operational resilience, and regulatory alignment each play decisive roles. For stakeholders, success will require integrated strategies that marry rigorous evidence generation with manufacturing adaptability and customized commercial execution.

Moving forward, the most durable advantage will accrue to organizations that can rapidly translate scientific advances into validated clinical benefits, maintain flexible and redundant supply networks, and engage clinicians with targeted educational and operational support. By doing so, stakeholders can ensure that the promise of new graft technologies is realized in improved patient outcomes and sustainable clinical adoption pathways. The concluding call to action is clear: align innovation with pragmatic implementation to capture emerging opportunities while safeguarding continuity of care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vascular Graft Market, by Product Type

  • 8.1. Biological Vascular Grafts
    • 8.1.1. Allografts
    • 8.1.2. Autografts
    • 8.1.3. Xenografts
  • 8.2. Synthetic Vascular Grafts
    • 8.2.1. Polyester
    • 8.2.2. Polytetrafluoroethylene
    • 8.2.3. Polyurethane

9. Vascular Graft Market, by Blood Vessel Diameter

  • 9.1. Large
  • 9.2. Small

10. Vascular Graft Market, by Indication

  • 10.1. Aortoiliac Bypass Surgery
  • 10.2. Cerebral Artery Bypass Surgery
  • 10.3. Coronary Artery Bypass Surgery
  • 10.4. Lower Extremity Bypass Surgery
  • 10.5. Peripheral Artery Bypass Surgery
  • 10.6. Renal Artery Bypass Surgery

11. Vascular Graft Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals & Clinics

12. Vascular Graft Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Vascular Graft Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Vascular Graft Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Vascular Graft Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Vascular Graft Market

17. China Vascular Graft Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Affluent Medical
  • 18.7. B. Braun Melsungen AG
  • 18.8. Becton, Dickinson and Company
  • 18.9. BIOVIC Sdn. Bhd.
  • 18.10. Boston Scientific Corporation
  • 18.11. Cardinal Health Inc.
  • 18.12. Cook Medical, Inc.
  • 18.13. Corcym S.r.l.
  • 18.14. CryoLife, Inc.
  • 18.15. Endologix Inc.
  • 18.16. Getinge AB
  • 18.17. Heart Medical Europe B.V.
  • 18.18. Japan Lifeline Co., Ltd.
  • 18.19. Lemaitre Vascular, Inc.
  • 18.20. Medtronic PLC
  • 18.21. Merit Medical Systems, Inc.
  • 18.22. Perouse Medical SAS by Vygon SAS
  • 18.23. Rua Life Sciences PLC
  • 18.24. Shanghai Suokang Medical Implants Co. Ltd.
  • 18.25. Terumo Corporation
  • 18.26. Vascular Graft Solutions Ltd.
  • 18.27. VUP Medical
  • 18.28. W. L. Gore & Associates, Inc.
  • 18.29. Xeltis B.V.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VASCULAR GRAFT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VASCULAR GRAFT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VASCULAR GRAFT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VASCULAR GRAFT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VASCULAR GRAFT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VASCULAR GRAFT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES VASCULAR GRAFT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA VASCULAR GRAFT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VASCULAR GRAFT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VASCULAR GRAFT MARKET SIZE, BY ALLOGRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VASCULAR GRAFT MARKET SIZE, BY ALLOGRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VASCULAR GRAFT MARKET SIZE, BY ALLOGRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AUTOGRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AUTOGRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AUTOGRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VASCULAR GRAFT MARKET SIZE, BY XENOGRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VASCULAR GRAFT MARKET SIZE, BY XENOGRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VASCULAR GRAFT MARKET SIZE, BY XENOGRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYESTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYESTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYESTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYTETRAFLUOROETHYLENE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYTETRAFLUOROETHYLENE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYTETRAFLUOROETHYLENE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYURETHANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYURETHANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYURETHANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VASCULAR GRAFT MARKET SIZE, BY LARGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VASCULAR GRAFT MARKET SIZE, BY LARGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VASCULAR GRAFT MARKET SIZE, BY LARGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VASCULAR GRAFT MARKET SIZE, BY SMALL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VASCULAR GRAFT MARKET SIZE, BY SMALL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VASCULAR GRAFT MARKET SIZE, BY SMALL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AORTOILIAC BYPASS SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AORTOILIAC BYPASS SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AORTOILIAC BYPASS SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VASCULAR GRAFT MARKET SIZE, BY CEREBRAL ARTERY BYPASS SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VASCULAR GRAFT MARKET SIZE, BY CEREBRAL ARTERY BYPASS SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VASCULAR GRAFT MARKET SIZE, BY CEREBRAL ARTERY BYPASS SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VASCULAR GRAFT MARKET SIZE, BY CORONARY ARTERY BYPASS SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VASCULAR GRAFT MARKET SIZE, BY CORONARY ARTERY BYPASS SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VASCULAR GRAFT MARKET SIZE, BY CORONARY ARTERY BYPASS SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VASCULAR GRAFT MARKET SIZE, BY LOWER EXTREMITY BYPASS SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VASCULAR GRAFT MARKET SIZE, BY LOWER EXTREMITY BYPASS SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VASCULAR GRAFT MARKET SIZE, BY LOWER EXTREMITY BYPASS SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VASCULAR GRAFT MARKET SIZE, BY PERIPHERAL ARTERY BYPASS SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VASCULAR GRAFT MARKET SIZE, BY PERIPHERAL ARTERY BYPASS SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VASCULAR GRAFT MARKET SIZE, BY PERIPHERAL ARTERY BYPASS SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VASCULAR GRAFT MARKET SIZE, BY RENAL ARTERY BYPASS SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VASCULAR GRAFT MARKET SIZE, BY RENAL ARTERY BYPASS SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VASCULAR GRAFT MARKET SIZE, BY RENAL ARTERY BYPASS SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VASCULAR GRAFT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VASCULAR GRAFT MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VASCULAR GRAFT MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VASCULAR GRAFT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VASCULAR GRAFT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VASCULAR GRAFT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VASCULAR GRAFT MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VASCULAR GRAFT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VASCULAR GRAFT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VASCULAR GRAFT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS VASCULAR GRAFT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL VASCULAR GRAFT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. GCC VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GCC VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. GCC VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 146. GCC VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 147. GCC VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 148. GCC VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. GCC VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. GCC VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. G7 VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. G7 VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. G7 VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 170. G7 VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 171. G7 VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 172. G7 VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. G7 VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. G7 VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. NATO VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. NATO VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. NATO VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 178. NATO VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 179. NATO VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 180. NATO VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. NATO VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. NATO VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES VASCULAR GRAFT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA VASCULAR GRAFT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)